Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Interim Results of the Phase III Portal Extension Trial of the Port Delivery System with Ranibizumab in Neovascular Age-Related Macular Degeneration

Published:2024-08 Issue: Volume: Page:
ISSN:2468-6530
Container-title:Ophthalmology Retina
language:en
Short-container-title:Ophthalmology Retina

Author:

Campochiaro Peter A.,Eichenbaum David^ORCID,Chang Margaret A.,Clark W. Lloyd,Graff Jordan M.,Le Pogam Sophie,Cavichini Cordeiro Melina,Gune Shamika^ORCID,Rabena Mel,Singh Natasha,Lin Stephanie,Callaway Natalia

Publisher

Elsevier BV

Reference37 articles.

1. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration;Solomon;Cochrane Database Syst Rev,2019

2. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration;Li;Cochrane Database Syst Rev,2020

3. Anti-vascular endothelial growth factor in neovascular age-related macular degeneration - a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems;Finger;BMC Ophthalmol,2020

4. Age-related macular degeneration Preferred Practice Pattern;Flaxel;Ophthalmology,2020

5. Real-world outcomes of anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration in the United States;Ciulla;Ophthalmol Retina,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP